ZMIZ2 and triple-negative breast carcinoma: These findings indicate ZMIZ2 plays a significant role in the malignant progression of lung cancer, consistent with the findings of previous studies on colon, triple-negative breast cancers, and hepatocellular carcinoma, underscoring the oncogenic role of ZMIZ2 across various malignancies [15–17].